Gilles GADEA

Dr. Gilles GADEA

Institut de Recherche en Cancérologie de Montpellier, Université de Montpellier, INSERM U1194, IRCM, F-34298 Montpellier, France
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Cell
Verified
Journal Article
Closed access
VSVictoria Sanz-Moreno
Victoria Sanz-Moreno
GGGilles GADEA
Gilles GADEA
JAJessica Ahn
Jessica Ahn
HPHugh Paterson
Hugh Paterson
PMPierfrancesco Marra
Pierfrancesco Marra
CMChristopher J. Marshall
Christopher J. Marshall

2 July 2007 in Journal of Cell Biology
Verified
Journal Article
Open access
GGGilles GADEA
Gilles GADEA
MTMarion de Toledo
Marion de Toledo
CAChristelle Anguille
Christelle Anguille
PRPierre Roux
Pierre Roux
In addition to its role in controlling cell cycle progression, the tumor suppressor protein p53 can also affect other cellular functions such as cell migration. In this study, we show that p53 deficiency in mouse embryonic fibroblasts cultured in three-dimensional matrices induces a switch from an elongated spindle morphology to a markedly spherical and flexible one associated with highly dynamic membrane blebs. These rounded, motile cells exhibit amoeboid-like movement and have considerably increased invasive properties. The morphological transition requires the RhoA–ROCK (Rho-associated coil-containing protein kinase) pathway and is prevented by RhoE. A similar p53-mediated transition is observed in melanoma A375P cancer cells. Our data suggest that genetic alterations of p53 in tumors are sufficient to promote motility and invasion, thereby contributing to metastasis.

1 October 2014 in European Journal of Cell Biology
Verified
Journal Article
Closed access
GGGilles GADEA
Gilles GADEA
ABAnne Blangy
Anne Blangy

1 October 2008 in Current Biology
Verified
Journal Article
Closed access
GGGilles GADEA
Gilles GADEA
VSVictoria Sanz-Moreno
Victoria Sanz-Moreno
ASAnnette Self
Annette Self
AGAnna Godi
Anna Godi
CMChristopher J. Marshall
Christopher J. Marshall

1 January 2013 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
JVJulian P. Venables
Julian P. Venables
JBJean-Philippe Brosseau
Jean-Philippe Brosseau
GGGilles GADEA
Gilles GADEA
RKRoscoe Klinck
Roscoe Klinck
PPPanagiotis Prinos
Panagiotis Prinos
Benoit ChabotBenoit Chabot
Benoit Chabot
Alternative splicing provides a critical and flexible layer of regulation intervening in many biological processes to regulate the diversity of proteins and impact cell phenotype. To identify alternative splicing differences that distinguish epithelial from mesenchymal tissues, we have investigated hundreds of cassette exons using a high-throughput reverse transcription-PCR (RT-PCR) platform. Extensive changes in splicing were noted between epithelial and mesenchymal tissues in both human colon and ovarian tissues, with many changes from mostly one splice variant to predominantly the other. Remarkably, many of the splicing differences that distinguish normal mesenchymal from normal epithelial tissues matched those that differentiate normal ovarian tissues from ovarian cancer. Furthermore, because splicing profiling could classify cancer cell lines according to their epithelial/mesenchymal characteristics, we used these cancer cell lines to identify regulators for these specific splicing signatures. By knocking down 78 potential splicing factors in five cell lines, we provide an extensive view of the complex regulatory landscape associated with the epithelial and mesenchymal states, thus revealing that RBFOX2 is an important driver of mesenchymal tissue-specific splicing.

18 September 2013 in Nature Communications
Verified
Journal Article
Closed access
PDF file
JVJulian P. Venables
Julian P. Venables
LLLaure Lapasset
Laure Lapasset
GGGilles GADEA
Gilles GADEA
PFPhilippe Fort
Philippe Fort
RKRoscoe Klinck
Roscoe Klinck
JTJamal Tazi
Jamal Tazi